Health Care Down as Novo Nordisk Plunges -- Health Care Roundup

Dow Jones

Mar 11, 2025

Health-care companies fell as traders retreated from some of the highest risk issues.

Shares of Novo Nordisk plunged 9% after patients in a clinical trial for the Danish obesity-drug maker's CagriSema product lost less weight than investors had anticipated. The boom in GLP-1 weight-loss drugs has been complicated by competition from compounding pharmacies such as Hims & Hers, and lofty investor expectations about the drugs' potential as a panacea.

Eli Lilly fell 4.6%. Illumina cut its growth forecast and said it would reduce capital expenditure by $100 million because China barred sales of the company's gene-sequencing machines.

CVS Health is testing stores that will offer full-service pharmacies but very limited retail, reflecting drug-store chains difficulties competing with mainline retailers in recent years.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

March 10, 2025 17:13 ET (21:13 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2518578634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518578634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2518578634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-11 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518578634","market":"sg","top_or_hot":-1,"title":"Health Care Down as Novo Nordisk Plunges -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as traders retreated from some of the highest risk issues. \n</p>\n<p>\n  Shares of Novo Nordisk plunged 9% after patients in a clinical trial for the Danish obesity-drug maker's CagriSema product lost less weight than investors had anticipated. The boom in GLP-1 weight-loss drugs has been complicated by competition from compounding pharmacies such as Hims &amp; Hers, and lofty investor expectations about the drugs' potential as a panacea. \n</p>\n<p>\n  Eli Lilly fell 4.6%. <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> cut its growth forecast and said it would reduce capital expenditure by $100 million because China barred sales of the company's gene-sequencing machines. \n</p>\n<p>\n  CVS Health is testing stores that will offer full-service pharmacies but very limited retail, reflecting drug-store chains difficulties competing with mainline retailers in recent years. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Down as Novo Nordisk Plunges -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Down as Novo Nordisk Plunges -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-11 05:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as traders retreated from some of the highest risk issues. \n</p>\n<p>\n  Shares of Novo Nordisk plunged 9% after patients in a clinical trial for the Danish obesity-drug maker's CagriSema product lost less weight than investors had anticipated. The boom in GLP-1 weight-loss drugs has been complicated by competition from compounding pharmacies such as Hims &amp; Hers, and lofty investor expectations about the drugs' potential as a panacea. \n</p>\n<p>\n  Eli Lilly fell 4.6%. <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> cut its growth forecast and said it would reduce capital expenditure by $100 million because China barred sales of the company's gene-sequencing machines. \n</p>\n<p>\n  CVS Health is testing stores that will offer full-service pharmacies but very limited retail, reflecting drug-store chains difficulties competing with mainline retailers in recent years. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2518578634","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518578634","pubTimestamp":1741641180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies fell as traders retreated from some of the highest risk issues.Shares of Novo Nordisk plunged 9% after patients in a clinical trial for the Danish obesity-drug maker's CagriSema product lost less weight than investors had anticipated. The boom in GLP-1 weight-loss drugs has been complicated by competition from compounding pharmacies such as Hims & Hers, and lofty investor expectations about the drugs' potential as a panacea.Eli Lilly fell 4.6%. Illumina cut its growth forecast and said it would reduce capital expenditure by $100 million because China barred sales of the company's gene-sequencing machines.CVS Health is testing stores that will offer full-service pharmacies but very limited retail, reflecting drug-store chains difficulties competing with mainline retailers in recent years.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVO":"诺和诺德","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"诺和诺德股价暴跌，医疗保健下降——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Health-care companies fell as traders retreated from some of the highest risk issues. \n\n\n  Shares of Novo Nordisk plunged 9% after patients in a clinical trial for the Danish obesity-drug maker's CagriSema product lost less weight than investors had anticipated. The boom in GLP-1 weight-loss drugs has been complicated by competition from compounding pharmacies such as Hims & Hers, and lofty investor expectations about the drugs' potential as a panacea. \n\n\n  Eli Lilly fell 4.6%. Illumina cut its growth forecast and said it would reduce capital expenditure by $100 million because China barred sales of the company's gene-sequencing machines. \n\n\n  CVS Health is testing stores that will offer full-service pharmacies but very limited retail, reflecting drug-store chains difficulties competing with mainline retailers in recent years. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 17:13 ET (21:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}